• Heather Agazzi, PhD: Her research interests include evaluation, diagnosis, and treatment of developmental disabilities, disruptive behavior disorders, and adverse childhood experiences.
  She is currently Site PI/Co-PI/Co-I for the following studies:
  
  1. Behavioral Health Workforce Education & Training Program at USF, funded by the Health Resources & Services Administration (HRSA), United States Department of Health
  2. An Integrated Nutrition Intervention through the Part C Early Intervention Services to Promote Healthy Eating Habits for Children with Autism Spectrum Disorders (NIH)
  3. DOCS Parenting Program

 For more information on HOT DOCS and DOCS K-5, visit https://health.usf.edu/medicine/pediatrics/child-development/hotdocs/overview. 

• Christopher Griffith, MD: His research interests include Fabry, Pompe, and Gaucher.   
  
  His current studies include:
  
  
  1. Sanofi Genzyme Rare Disease Registry - A Multi-Center, International, Longitudinal, Observational program designed to track natural history and outcomes of patients with Gaucher, Fabry, MPSI, and Pompe Disease (Gaucher registry, Fabry registry, MPSI registry, Pompe registry)
  2. A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease
     
     
• Judith Ranells, MD: Her research interests include Rett Syndrome, identification of novel genes, and associated phenotypes.  
  
  She is currently site PI for the following study:  
  
  
  1. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women with Rett Syndrome
     
     
• Amarilis Sanchez-Valle, MD: Her research interests include inborn errors of metabolism, specifically, Phenylketonuria, Fatty Acid Oxidation Disorders, and Urea Cycle Disorders.    
  
  She is currently the site PI for the following studies:     
  
  1. A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria and Plasma Phe Levels > 600 μmol/L
  2. Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
  3. A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs. Diet-Only Control) Design
  4. An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with hypophosphatasia
  5. A Prospective Study Investigating the Natural History of Adults with Phenylketonuria (PKU) due to Phenylalanine Hydroxylase Deficiency      

• Carina A. Rodriguez, MD: Her research interests include HIV/STI prevention and treatment, vaccinology, infections in immunocompromised patients and tuberculosis. 
  
  She is currently site PI or Co-PI for NIH-funded national and international networks including:
  
  1. COVID-19 Prevention Network (CoVPN)
  2. The Congenital and Perinatal Rare Disease Clinical Research Consortium
  3. The Adolescent Trials Networks
  
  Her other active studies include: 
  
  
  1. ACTG A5418 NIH/NIAID: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease.
  2. Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Site Consortium related protocols
  3. A Phase 3 open-label expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 primary and booster SARS-CoV-2 vaccine in healthy children 6 months to less than 6 years of age
  4. A Phase 2/3, two part, open-label, dose-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age
  5. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years with a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
  6. Congenital and Perinatal Rare Disease Clinical Research Consortium relates protocols on acute flaccid myelitis, neonatal enterovirus, cytomegalovirus infections or their treatments.
  7. A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Remdesivir in Participants from Birth to < 18 Years of Age with COVID-19
  8. Pharmacokinetics, Safety, and Antiviral Activity of the Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

• Claudia Espinosa, MD, MSc: Her research interests include perinatal infections, surveillance of respiratory infections, and infection prevention. 
  
  She is currently PI for the following studies:
  
  
  1. A neonatal enterovirus ad human parechovirus viral sepsis study to define the natural history and predictors of morbidity and mortality of these infections in neonates NIAID/University Cincinnati
  2. A prospective study of Acute Flaccid Myelitis to define natural history, risk factors, and pathogenic mechanisms of this disease. UAB/NIH
  3. A phase 2 randomized, double blind, placebo-controlled, study to evaluate an antiviral in children infected with RSV
  4. A phase 3, multicenter, randomized, partially blinded, palivizumab controlled study to evaluate the safety, efficacy, and pharmacokinetics of a monoclonal antibody in infants and children at increased risk for severe RSV disease
  5. A phase 2 open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetics, occurrence of antidrug antibody, and efficacy of nirsevimab in immunocompromised children who are ≤ 24 months of age at the time of dose administration

• Maya Balakrishnan, MD: Her research interests include quality improvement, its clinical applications, as well as its effectiveness on neonatal abstinence syndrome.
  
  She is currently Site Co-I for the following studies:
  
  
  
  1. Eating, Sleeping, Consoling for Neonatal Opioid Withdrawal Syndrome (ACT NOW ESC): A function-based assessment and management approach (NIH, NICHD)
  2. MATernal and Infant Network to Understand Outcomes Associated with Treatment for Opioid Use Disorder during Pregnancy (MAT-LINK 2) Expansion Project (CDC, PHII)
     
     
• Jaime Flores-Torres, MD: His research interests include Hypoxic Ischemic Encephalopathy, neonatal seizures, prenatal consultation, and neonatal palliative care. 
  
  He is currently Site PI for the following clinical trials: 
  
  
  1. Infant Bacterial Therapeutics AB – IBP9414-020: A randomized, double blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis – The Connection study
  2. Abbott Laboratories – AL35: Evaluation of Preterm Infants Fed Post-Discharge Preterm Infant Formula with Added Human Milk Oligosaccharide 2’-Fucosyllactose
     
     
• Steven Ford, MD: His research interests include neonatal nutrition and intestinal rehabilitation. 
  
  He is currently Site PI for the following clinical trials: 
  
  
  1. Oak Hill Bio- OHB-607-202, A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants
  2. Premacure AB, A Member of the Shire Group of Companies – SHP607-203, Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants
  3. Abbott Nutrition, Abbott Laboratories, AL-46, Growth and Tolerance of Premature Infants Fed an Experimental Human Milk Fortifier

• Thao (Tina) Ho, DO: Her research interests include the development of gut microbiota, its influence on health and impact on risk for diseases in preterm infants.
  
  She is currently Site PI for the following studies:
  
  
  1. Enteral Iron Dosage and Gut Health: A Randomized Double Blinded Study (NIH, NHLBI: 5K23HL150300) Anemia and Gut Microbiota: An Observational Study

• Tara Randis, MD: Her research interests include the mechanisms by which maternal pathogens contribute to adverse pregnancy outcomes and neonatal morbidity and mortality. 
  
  She is currently Site PI for the following studies: 
  
  
  1. NICU Antibiotics and Outcomes Trial (NIH, NICHD)

• Tanner Wright, MD: His research interests include maternal-infant dyads affected by opioid use.
  
  He is currently Site PI/Co-PI for the following studies:
  
  
  1. Eating, Sleeping, Consoling for Neonatal Opioid Withdrawal Syndrome (ACT NOW ESC): A function-based assessment and management approach (NIH, NICHD)
  2. MATernal and Infant Network to Understand Outcomes Associated with Treatment for Opioid Use Disorder during Pregnancy (MAT-LINK 2) Expansion Project (CDC, PHII)
  3. Adverse Childhood Experiences: Impact on Maternal and Infant Outcomes Associated with Opioid Use Disorder USF Women’s Health Collaborative- PNC Bank Sponsored Seed Grant

• Adam B. Lewin, PhD, ABPP: His research interests include Tourette, Obsessive Compulsive, Misophonia, and related disorders.
  
  He is currently Site PI for the following grants:
  
  
  1. Transdiagnostic Treatment for Youth with Misophonia (Clinical Trial; Funded by the Ream Foundation)
  2. Screening for Tourette and Tic Disorders (Funded by CDC)
  3. Applying Statistical Measures to Improve identification of Tics and Tic Disorders (Funded by CDC)
  4. Developing assessment tools for Misophonia (Funded by the Ream Foundation)